Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mifepristone and Eribulin in combination · 1 trial · 7 indications
In the dose escalation phase: MTD time frame is within 28 days of first dose (Cycle 1)
| Arm | Type | Description |
|---|---|---|
| Mifepristone and Eribulin in combination | EXPERIMENTAL | Single Arm |
| Name | Type | Description |
|---|---|---|
| Mifepristone and Eribulin in combination | DRUG | Single Arm, Two Parts Part 1: Dose Escalation Phase to determine MTD and RP2D in up to 20 patients Part 2: Dose Expansion Phase at RP2D in 20 patients |
Inclusion Criteria: 1. Informed consent given prior to study-specific screening procedures 2. ≥ 18 years old Part 2, dose expansion: 1. Diagnosis of TNBC: \< 1% cells positive for ER/progesterone receptor, and HER2 IHC score of 0 or 1, or FISH HER2+ ratio of less than 1.8; patients with low ER IH...
Top 20 of 92 competitors
Mifepristone is being developed by Corcept Therapeutics for Cushing's Syndrome, Cushing's Disease, and Major Depressive Disorder. It is a small molecule in Phase 3 clinical development for these endocrine and psychiatric conditions. The drug is investigational and has not been approved for these indications.
Corcept Therapeutics Incorporated (NASDAQ: CORT) is developing Mifepristone. The company is conducting clinical trials for the drug in indications including Cushing's Syndrome, Cushing's Disease, and Major Depressive Disorder. Corcept Therapeutics is the developer of this investigational small molecule.
Mifepristone is in Phase 3 clinical development for Cushing's Syndrome, Cushing's Disease, and Major Depressive Disorder. The drug is investigational and has not been approved by regulatory authorities for these indications. Corcept Therapeutics is conducting the clinical development program.
Mifepristone has completed five clinical trials. These include NCT00455442, a Phase 2 study in weight-gain prevention; NCT00698022, a Phase 1 study in healthy volunteers; NCT03258372 and NCT03259542, Phase 1 drug-drug interaction studies; and one additional completed trial. All trials are completed with no active studies ongoing.
Mifepristone is a small molecule that acts as a glucocorticoid receptor antagonist. By blocking the glucocorticoid receptor, it is being studied for its effects in Cushing's Syndrome, Cushing's Disease, and Major Depressive Disorder. This mechanism is relevant to conditions involving cortisol dysregulation.
Mifepristone is the active ingredient in Korlym, a medication approved for Cushing's syndrome. However, the data provided does not specify whether the Mifepristone in development by Corcept Therapeutics is the same product as Korlym. The drug is being studied in Phase 3 trials for related indications.